Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Research Report 2023
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
According to QYResearch’s new survey, global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market is projected to reach US$ 1106.4 million in 2029, increasing from US$ 767 million in 2022, with the CAGR of 5.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market is projected to reach US$ 1106.4 million in 2029, increasing from US$ 767 million in 2022, with the CAGR of 5.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- BioMarin Pharmaceutical
- Sangamo Therapeutics
- Amicus Therapeutics
- Roche
- Pfizer
- NightstaRx
- MeiraGTx
- Sarepta Therapeutics
- Neurocrine Biosciences
- Voyager Therapeutics
- Asklepios Biopharmaceutical
- Single-stranded AAV (ssAAV)
- Self-complementary AAV (scAAV)
- Hemophilia
- Ophthalmology
- Lysosomal Storage Disorders
- Neurological Disorders
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Single-stranded AAV (ssAAV)
1.2.3 Self-complementary AAV (scAAV)
1.3 Market by Application
1.3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hemophilia
1.3.3 Ophthalmology
1.3.4 Lysosomal Storage Disorders
1.3.5 Neurological Disorders
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Perspective (2018-2029)
2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Trends by Region
2.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Region (2018-2023)
2.2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029)
2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Dynamics
2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Trends
2.3.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
2.3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
2.3.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Revenue
3.1.1 Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Revenue (2018-2023)
3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio
3.4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
3.5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Area Served
3.6 Key Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Solution and Service
3.7 Date of Enter into Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BREAKDOWN DATA BY TYPE
4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Type (2018-2023)
4.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029)
5 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BREAKDOWN DATA BY APPLICATION
5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Application (2018-2023)
5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
6.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
6.4 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
7.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
8.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
9.2 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
9.4 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
10.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 BioMarin Pharmaceutical
11.1.1 BioMarin Pharmaceutical Company Detail
11.1.2 BioMarin Pharmaceutical Business Overview
11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.1.4 BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.1.5 BioMarin Pharmaceutical Recent Development
11.2 Sangamo Therapeutics
11.2.1 Sangamo Therapeutics Company Detail
11.2.2 Sangamo Therapeutics Business Overview
11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.2.4 Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.2.5 Sangamo Therapeutics Recent Development
11.3 Amicus Therapeutics
11.3.1 Amicus Therapeutics Company Detail
11.3.2 Amicus Therapeutics Business Overview
11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.3.4 Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.3.5 Amicus Therapeutics Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.4.4 Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.4.5 Roche Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.5.4 Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 NightstaRx
11.6.1 NightstaRx Company Detail
11.6.2 NightstaRx Business Overview
11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.6.4 NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.6.5 NightstaRx Recent Development
11.7 MeiraGTx
11.7.1 MeiraGTx Company Detail
11.7.2 MeiraGTx Business Overview
11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.7.4 MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.7.5 MeiraGTx Recent Development
11.8 Sarepta Therapeutics
11.8.1 Sarepta Therapeutics Company Detail
11.8.2 Sarepta Therapeutics Business Overview
11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.8.4 Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.8.5 Sarepta Therapeutics Recent Development
11.9 Neurocrine Biosciences
11.9.1 Neurocrine Biosciences Company Detail
11.9.2 Neurocrine Biosciences Business Overview
11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.9.4 Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.9.5 Neurocrine Biosciences Recent Development
11.10 Voyager Therapeutics
11.10.1 Voyager Therapeutics Company Detail
11.10.2 Voyager Therapeutics Business Overview
11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.10.4 Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.10.5 Voyager Therapeutics Recent Development
11.11 Asklepios Biopharmaceutical
11.11.1 Asklepios Biopharmaceutical Company Detail
11.11.2 Asklepios Biopharmaceutical Business Overview
11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.11.4 Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.11.5 Asklepios Biopharmaceutical Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Single-stranded AAV (ssAAV)
1.2.3 Self-complementary AAV (scAAV)
1.3 Market by Application
1.3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hemophilia
1.3.3 Ophthalmology
1.3.4 Lysosomal Storage Disorders
1.3.5 Neurological Disorders
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Perspective (2018-2029)
2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Trends by Region
2.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Region (2018-2023)
2.2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029)
2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Dynamics
2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Trends
2.3.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
2.3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
2.3.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Revenue
3.1.1 Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Revenue (2018-2023)
3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio
3.4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
3.5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Area Served
3.6 Key Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Solution and Service
3.7 Date of Enter into Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BREAKDOWN DATA BY TYPE
4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Type (2018-2023)
4.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029)
5 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BREAKDOWN DATA BY APPLICATION
5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Application (2018-2023)
5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
6.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
6.4 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
7.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
8.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
9.2 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
9.4 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
10.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 BioMarin Pharmaceutical
11.1.1 BioMarin Pharmaceutical Company Detail
11.1.2 BioMarin Pharmaceutical Business Overview
11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.1.4 BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.1.5 BioMarin Pharmaceutical Recent Development
11.2 Sangamo Therapeutics
11.2.1 Sangamo Therapeutics Company Detail
11.2.2 Sangamo Therapeutics Business Overview
11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.2.4 Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.2.5 Sangamo Therapeutics Recent Development
11.3 Amicus Therapeutics
11.3.1 Amicus Therapeutics Company Detail
11.3.2 Amicus Therapeutics Business Overview
11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.3.4 Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.3.5 Amicus Therapeutics Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.4.4 Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.4.5 Roche Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.5.4 Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 NightstaRx
11.6.1 NightstaRx Company Detail
11.6.2 NightstaRx Business Overview
11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.6.4 NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.6.5 NightstaRx Recent Development
11.7 MeiraGTx
11.7.1 MeiraGTx Company Detail
11.7.2 MeiraGTx Business Overview
11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.7.4 MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.7.5 MeiraGTx Recent Development
11.8 Sarepta Therapeutics
11.8.1 Sarepta Therapeutics Company Detail
11.8.2 Sarepta Therapeutics Business Overview
11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.8.4 Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.8.5 Sarepta Therapeutics Recent Development
11.9 Neurocrine Biosciences
11.9.1 Neurocrine Biosciences Company Detail
11.9.2 Neurocrine Biosciences Business Overview
11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.9.4 Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.9.5 Neurocrine Biosciences Recent Development
11.10 Voyager Therapeutics
11.10.1 Voyager Therapeutics Company Detail
11.10.2 Voyager Therapeutics Business Overview
11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.10.4 Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.10.5 Voyager Therapeutics Recent Development
11.11 Asklepios Biopharmaceutical
11.11.1 Asklepios Biopharmaceutical Company Detail
11.11.2 Asklepios Biopharmaceutical Business Overview
11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.11.4 Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
11.11.5 Asklepios Biopharmaceutical Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Single-stranded AAV (ssAAV)
Table 3. Key Players of Self-complementary AAV (scAAV)
Table 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2023)
Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2024-2029)
Table 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Trends
Table 11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
Table 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
Table 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
Table 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Players (2018-2023)
Table 16. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Table 17. Ranking of Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Solution and Service
Table 21. Date of Enter into Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2018-2023)
Table 25. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2024-2029)
Table 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Application (2018-2023)
Table 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Application (2024-2029)
Table 31. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 46. BioMarin Pharmaceutical Company Detail
Table 47. BioMarin Pharmaceutical Business Overview
Table 48. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 49. BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 50. BioMarin Pharmaceutical Recent Development
Table 51. Sangamo Therapeutics Company Detail
Table 52. Sangamo Therapeutics Business Overview
Table 53. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 54. Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 55. Sangamo Therapeutics Recent Development
Table 56. Amicus Therapeutics Company Detail
Table 57. Amicus Therapeutics Business Overview
Table 58. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 59. Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 60. Amicus Therapeutics Recent Development
Table 61. Roche Company Detail
Table 62. Roche Business Overview
Table 63. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 64. Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 65. Roche Recent Development
Table 66. Pfizer Company Detail
Table 67. Pfizer Business Overview
Table 68. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 69. Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 70. Pfizer Recent Development
Table 71. NightstaRx Company Detail
Table 72. NightstaRx Business Overview
Table 73. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 74. NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 75. NightstaRx Recent Development
Table 76. MeiraGTx Company Detail
Table 77. MeiraGTx Business Overview
Table 78. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 79. MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 80. MeiraGTx Recent Development
Table 81. Sarepta Therapeutics Company Detail
Table 82. Sarepta Therapeutics Business Overview
Table 83. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 84. Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 85. Sarepta Therapeutics Recent Development
Table 86. Neurocrine Biosciences Company Detail
Table 87. Neurocrine Biosciences Business Overview
Table 88. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 89. Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 90. Neurocrine Biosciences Recent Development
Table 91. Voyager Therapeutics Company Detail
Table 92. Voyager Therapeutics Business Overview
Table 93. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 94. Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 95. Voyager Therapeutics Recent Development
Table 96. Asklepios Biopharmaceutical Company Detail
Table 97. Asklepios Biopharmaceutical Business Overview
Table 98. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 99. Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 100. Asklepios Biopharmaceutical Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
Table 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Single-stranded AAV (ssAAV)
Table 3. Key Players of Self-complementary AAV (scAAV)
Table 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2023)
Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2024-2029)
Table 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Trends
Table 11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
Table 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
Table 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
Table 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Players (2018-2023)
Table 16. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Table 17. Ranking of Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Solution and Service
Table 21. Date of Enter into Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2018-2023)
Table 25. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2024-2029)
Table 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Application (2018-2023)
Table 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Application (2024-2029)
Table 31. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 46. BioMarin Pharmaceutical Company Detail
Table 47. BioMarin Pharmaceutical Business Overview
Table 48. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 49. BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 50. BioMarin Pharmaceutical Recent Development
Table 51. Sangamo Therapeutics Company Detail
Table 52. Sangamo Therapeutics Business Overview
Table 53. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 54. Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 55. Sangamo Therapeutics Recent Development
Table 56. Amicus Therapeutics Company Detail
Table 57. Amicus Therapeutics Business Overview
Table 58. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 59. Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 60. Amicus Therapeutics Recent Development
Table 61. Roche Company Detail
Table 62. Roche Business Overview
Table 63. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 64. Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 65. Roche Recent Development
Table 66. Pfizer Company Detail
Table 67. Pfizer Business Overview
Table 68. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 69. Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 70. Pfizer Recent Development
Table 71. NightstaRx Company Detail
Table 72. NightstaRx Business Overview
Table 73. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 74. NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 75. NightstaRx Recent Development
Table 76. MeiraGTx Company Detail
Table 77. MeiraGTx Business Overview
Table 78. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 79. MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 80. MeiraGTx Recent Development
Table 81. Sarepta Therapeutics Company Detail
Table 82. Sarepta Therapeutics Business Overview
Table 83. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 84. Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 85. Sarepta Therapeutics Recent Development
Table 86. Neurocrine Biosciences Company Detail
Table 87. Neurocrine Biosciences Business Overview
Table 88. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 89. Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 90. Neurocrine Biosciences Recent Development
Table 91. Voyager Therapeutics Company Detail
Table 92. Voyager Therapeutics Business Overview
Table 93. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 94. Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 95. Voyager Therapeutics Recent Development
Table 96. Asklepios Biopharmaceutical Company Detail
Table 97. Asklepios Biopharmaceutical Business Overview
Table 98. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 99. Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023) & (US$ Million)
Table 100. Asklepios Biopharmaceutical Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type: 2022 VS 2029
Figure 3. Single-stranded AAV (ssAAV) Features
Figure 4. Self-complementary AAV (scAAV) Features
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application: 2022 VS 2029
Figure 7. Hemophilia Case Studies
Figure 8. Ophthalmology Case Studies
Figure 9. Lysosomal Storage Disorders Case Studies
Figure 10. Neurological Disorders Case Studies
Figure 11. Others Case Studies
Figure 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report Years Considered
Figure 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region: 2022 VS 2029
Figure 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Players in 2022
Figure 17. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
Figure 19. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 21. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 25. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Nordic Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2029)
Figure 33. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 41. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 45. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. BioMarin Pharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 48. Sangamo Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 49. Amicus Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 50. Roche Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 51. Pfizer Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 52. NightstaRx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 53. MeiraGTx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 54. Sarepta Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 55. Neurocrine Biosciences Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 56. Voyager Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 57. Asklepios Biopharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Figure 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type: 2022 VS 2029
Figure 3. Single-stranded AAV (ssAAV) Features
Figure 4. Self-complementary AAV (scAAV) Features
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application: 2022 VS 2029
Figure 7. Hemophilia Case Studies
Figure 8. Ophthalmology Case Studies
Figure 9. Lysosomal Storage Disorders Case Studies
Figure 10. Neurological Disorders Case Studies
Figure 11. Others Case Studies
Figure 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report Years Considered
Figure 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region: 2022 VS 2029
Figure 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Players in 2022
Figure 17. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
Figure 19. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 21. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 25. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Nordic Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2029)
Figure 33. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 41. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 45. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. BioMarin Pharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 48. Sangamo Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 49. Amicus Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 50. Roche Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 51. Pfizer Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 52. NightstaRx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 53. MeiraGTx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 54. Sarepta Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 55. Neurocrine Biosciences Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 56. Voyager Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 57. Asklepios Biopharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
